AbbVie (ABBV) Reports Earnings Tomorrow: What To Expect

Pharmaceutical company AbbVie (NYSE:ABBV) will be reporting results this Friday before market open. Here’s what you need to ...

Assessing AbbVie’s Value After 25.5% Rally and Oncology Growth Moves in 2025

If you own AbbVie stock or are thinking about adding it to your portfolio, you’ve probably noticed the ups and downs lately.
The Malaysian Reserve

The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year

Allergan Aesthetics gives patients exciting BOTOX® Cosmetic offers only in the Allē app Buy one $50 gift card, get one free, ...
Fierce Biotech

AbbVie halts development of Dragonfly cancer asset midflight

AbbVie has scrapped an asset from its ongoing collaboration with Dragonfly Therapeutics, a spokesperson for the Chicago ...

AbbVie's Rinvoq Hits Main Endpoints in Vitiligo Studies

AbbVie on Wednesday said the replicate Phase 3 studies met their co-primary endpoints of reduction in de-pigmentation over the entire body and the face in adults and adolescents with non-segmental ...

Assessing AbbVie (ABBV) Valuation as Shares Approach Recent Highs and Outpace Sector Returns

AbbVie (ABBV) has seen its stock tick slightly lower this week, with shares down 0.2% today but still up 3% over the past ...
Le Lézard

AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo

AbbVie today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ®;15 mg, once daily  in adult and adolescent patients ...
TipRanks on MSN

AbbVie reports results from Phase 3 studies evaluating upadacitinib

AbbVie (ABBV) announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of ...